Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to a number of media reports today, Medivation’s investigational drug MDV3100 appears to have a relatively good safety profile, although five patients who received MDV3100 in the completed Phase III trial did have seizures.
Filed under: Drugs in development, Management, Treatment | Tagged: efficacy, mCRPC, MDV3100, Phase III, safety | 5 Comments »
According to a Reuters report and a media release this morning, Medivation has announced that interim results of the Phase III AFFIRM trial showed a 4.8-month survival benefit for treatment with MDV3100 compared to a placebo in men with metastatic, castration-resistant prostate cancer after treatment with docetaxel-based chemotherapy.
Filed under: Drugs in development, Management, Treatment | Tagged: AFFIRM, mCRPC, MDV3100, outcome | 2 Comments »
Some readers may be interested in in reading a commentary by John Carroll on the FierceBiotech web site, where he discusses whether MDV3100 is going to be able to “match up” to abiraterone acetate — always assuming that MDV3100 can also show a survival benefit in men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, mCRPC, MDV3100 | 2 Comments »
So lots of posters and and presentations this morning, but not a lot of actionable information for patients (as far a we could tell). Among the more interesting papers were the following:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Gleason score, MDV3100, mortality, OGX-011, positive, risk, surgical. margin | Leave a Comment »
As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs.
Filed under: Drugs in development | Tagged: abiraterone, ASCO, investment, MDV3100 | 1 Comment »
Patients and others with a strong interest in understanding the ways in which new drugs like abiraterone acetate and MDV3100 are likely to change the way we treat advanced forms of prostate cancer might be interested in a webcast based on a satellite symposium held at the recent Genitourinary Cancers Symposium in Orlando.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, CRPC, MDV3100 | Leave a Comment »
According to a media release issued earlier today, Medivation and Astellas Pharma have enrolled the first patient into a new Phase III clinical trial of MDV3100.
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, MDV3100, Phase III, trial | Leave a Comment »
There have been numerous media reports about on-line publication of data from a Phase I/II clinical trial of MDV3100 over the past 2 days.
Filed under: Drugs in development | Tagged: MDV3100 | Leave a Comment »
According to an e-mail from our friends at Us TOO the AFFIRM trial (A study evaluating the eFFicacy and safety of Investigational dRug MDV3100 in men with advanced prostate cancer) has started to enroll patients in the USA. It had started to enroll patients in Europe earlier this month.
Filed under: Drugs in development | Tagged: AFFIRM, MDV3100, Phase III, trial | 5 Comments »
According to a media release this morning, the global pharmaceutical company Astellas has licensed rights to commercialize Medivation’s investigational prostate cancer drug MDV3100.
Filed under: Drugs in development | Tagged: MDV3100 | Leave a Comment »
According to a media release from Medivation, Inc. earlier today, the company has treated the first patient in a Phase III clinical trial of the novel androgen receptor antagonist MDV3100 in advanced prostate cancer.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, MDV3100 | 2 Comments »
On Saturday there were two major prostate cancer sessions and additional poster sessions that included prostate cancer-related material at the annual meeting of the American Society for Clinical Oncology.
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100, OGX-011, PROSTVAC-VF, vaccines | Leave a Comment »
There are several stories on the Web today about a forthcoming article in Science giving data about a phase I/II trial of MDV3100.
Filed under: Drugs in development, Management, Treatment | Tagged: MDV3100 | Leave a Comment »
There are six new reports in today’s news, of which the most immediately important would seem to be: How men manage their “fear” while on active surveillance “Cancer anxiety” and early use of hormonal therapy Approval for a Phase III clinical trial of MDV3100
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active suirveillance, cancer anxiety, denosumab, forkhead transcription factors, FOX factors, hormone therapy, MDV3100, testosterone | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site